Phase 4
Completed N=61
Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine
Source: ClinicalTrials.gov NCT01778413 ↗Enrolled (actual)
61
Serious AEs
0.0%
Results posted
Jul 2025
Primary outcomePrimary: Proportion of Patients Free of Treatment Failure (Noncompleter = Failure) at 24 Weeks. — 30; 31; 0; 0 Participants
◆ Published Evidence
Emerging
14citations · ~2 / year
A maintenance 3-day-per-week schedule with the single tablet regimen efavirenz/emtricitabine/tenofovir disoproxil fumarate is effective and decreases sub-clinical toxicity.
Summary
The main objective is to determine the feasibility of maintaining virologic suppression on standard plasma viral load by dose reduction of ATRIPLA ®.
Linked Publications (3)
-
A maintenance 3-day-per-week schedule with the single tablet regimen efavirenz/emtricitabine/tenofovir disoproxil fumarate is effective and decreases sub-clinical toxicity.
-
Effects on immune system and viral reservoir of a short-cycle antiretroviral therapy in virologically suppressed HIV-positive patients.
-
Short-cycle three-day-per-week efavirenz/emtricitabine/tenofovir disoproxil fumarate therapy: a seven-year extension study.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Proportion of Patients Free of Treatment Failure (Noncompleter = Failure) at 24 Weeks. |
30; 31; 0; 0 | — |
| SECONDARY The Proportion of Patients With Ultrasensitive Viral Load (<1 Copy / mL) After 24 Weeks. |
— | — |
| SECONDARY The Change From Baseline to 24 Weeks in the Viral Reservoir in Peripheral Blood Mononuclear Cells |
— | — |
| SECONDARY Immunological |
— | — |
| SECONDARY Changes in Plasma Levels of Efavirenz. |
— | — |
| SECONDARY Changes in Sleep Quality (Pittsburgh Sleep Quality Index). |
— | — |
| SECONDARY General Safety (Report Adverse Events, Serious Adverse Events and Treatment Discontinuation Due to Adverse Events) |
— | — |
| SECONDARY Changes in Plasma Levels of Vitamin D. |
— | — |
| SECONDARY Changes in Lipid Profile. |
— | — |
| SECONDARY Changes in Estimated Glomerular Filtration Rate. |
— | — |
Eligibility Criteria
Inclusion Criteria
- Adults (≥ 18 years)
- HIV-1 infection, clinical stability, and treatment with ATRIPLA ® for the past two years.
- Standard plasma viral load below the limit of detection for at least 2 years.
- CD4 count above 350/mm3 at the time of the consideration for the study.
- Negative pregnancy test in women of childbearing age, and commitment acceptable contraceptive use for at least 2 weeks before day 1 and until at least 6 months after the last dose of study drug.
- Patients should be given written informed consent
- In the opinion of the investigator, be able to follow the design of the protocol visits
Exclusion Criteria
- Patients who have experienced virologic failure prior to any antiretroviral regimen
- Evidence of previous mutations versus efavirenz, tenofovir and emtricitabine
- Use of any other chronic treatment plus ATRIPLA has been introduced in the 6 months prior to entry of the patient in the study
- Any contraindication to study drug
- Any condition not ensure proper adherence to the study at the discretion of the attending physician of the patient
- Uncontrolled preexisting psychiatric illness
- Any current sign of alcoholism or other drug use.
Data sourced from ClinicalTrials.gov (NCT01778413) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.